Gilead Sciences (GILD) Assets Average (2009 - 2026)
Gilead Sciences (GILD) posted Assets Average of $57.7 billion for Q1 2026, down 1.92% quarter-over-quarter from $58.8 billion in Q4 2025, and little changed year-on-year from $57.7 billion in Q1 2025.
Gilead Sciences (GILD) Assets Average (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Assets Average for 18 consecutive years, with $57.7 billion the latest figure, recorded in Q1 2026.
- Assets Average for Q1 2026 came in at $57.7 billion, changed 0.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $57.7 billion (changed 0.11% YoY), and the FY2025 annual result was $59.0 billion, down 2.56% from the prior year.
- Assets Average was $57.7 billion for Q1 2026 at Gilead Sciences, down from $58.8 billion in the prior quarter.
- Over five years, Assets Average peaked at $65.5 billion in Q1 2022 and troughed at $54.1 billion in Q3 2024.
- Average Assets Average over 5 years is $59.7 billion, with a median of $59.2 billion recorded in 2024.
- Year-over-year, Assets Average dropped 13.32% in 2024 and gained 5.69% in 2025.
- Over 5 years, Assets Average stood at $62.9 billion in 2022, then dropped by 0.98% to $62.2 billion in 2023, then fell by 8.82% to $56.8 billion in 2024, then advanced by 3.56% to $58.8 billion in 2025, then decreased by 1.92% to $57.7 billion in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $57.7 billion in Q1 2026, $58.8 billion in Q4 2025, and $57.1 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 114.53 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 200.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 135.21 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 114.04 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 132.78 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 91.55 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 57.65 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 208.08 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 29.46 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.65 Bn |
| Dec 31, 2025 | 58.78 Bn |
| Sep 30, 2025 | 57.13 Bn |
| Jun 30, 2025 | 56.08 Bn |
| Mar 31, 2025 | 57.71 Bn |
| Dec 31, 2024 | 56.76 Bn |
| Sep 30, 2024 | 54.05 Bn |
| Jun 30, 2024 | 54.94 Bn |
| Mar 31, 2024 | 59.21 Bn |
| Dec 31, 2023 | 62.25 Bn |
| Sep 30, 2023 | 62.36 Bn |
| Jun 30, 2023 | 62.11 Bn |
| Mar 31, 2023 | 62.52 Bn |
| Dec 31, 2022 | 62.86 Bn |
| Sep 30, 2022 | 62.71 Bn |
| Jun 30, 2022 | 62.98 Bn |
| Mar 31, 2022 | 65.52 Bn |
| Dec 31, 2021 | 67.53 Bn |
| Sep 30, 2021 | 67.54 Bn |
| Jun 30, 2021 | 67.74 Bn |